What is Chronic Myelogenous Leukemia (CML) ?

Chronic Myelogenous Leukemia, or CML, also called 'Chronic Myeloid Leukemia', is a cancer or cancerous disease of the 'bone marrow' and blood distinguished by myeloid cells proliferating out of control. It is a clonal stem cell disorder wherein aberrant white blood cells proliferate in the bloodstream and bone marrow. Unlike acute leukemias that progress rapidly, CML usually develops slowly and evolves through defined clinical phases.

Identification of the Philadelphia chromosome and the BCR-ABL1 hybrid gene transformed the way CML is understood and managed. At present, CML is considered one of the most effectively managed hematologic cancers due to the development of targeted therapies that inhibit the protein driving the disease.

How Does CML Form and What Are Its Three Clinical Phases?

CML arises from a genetic abnormality in hematopoietic stem cells. This abnormality results in excessive production of granulocytes — a type of white blood cell — along with their immature precursors. Over time, these abnormal cells crowd out healthy blood cells.

CML progresses in three phases:

• Chronic Phase
• Accelerated Phase
• Blast Phase (Blast Crisis)

The majority of patients receive a diagnosis during the chronic period. where disease control with medication is highly effective.

What are the Causes and Risk factors of Chronic Myelogenous Leukemia?

CML results from a genetic translocation that occurs between chromosomes 9 and 22. The Philadelphia chromosome emerges from this genetic exchange, which generates the BCR-ABL1 fusion gene.

The BCR-ABL1 gene generates an abnormal tyrosine kinase protein that continuously signals white blood cells to multiply uncontrollably.

This mutation:

• Occurs after birth (acquired)
• Is not inherited
• Is not passed to children

Risk factors include:

• Increasing age
• Male gender
• Rare exposure to high-dose radiation

CML is not known to be caused by lifestyle factors, including stress, smoking, or food.

What Are the Symptoms of CML?

Routine blood tests are used to identify many people who are asymptomatic at the time of diagnosis.

Symptoms include:

• Excessive tiredness
• Sweating at night
• Losing weight without trying
• Fever
• An enlarged spleen (which causes a bloated abdomen or abdominal pain)
• Bruising easily
• Difficulty breathing (due to anemia)

As CML progresses, symptoms become more pronounced.

What are the Phases of CML ?

Chronic Phase

• Less than 10% blast cells in blood or bone marrow
• Mild or no symptoms
• Best response to therapy

The majority of patients are diagnosed here.

Accelerated Phase

• 10-19% blast cells
• Rising white blood cell count despite treatment
• Progression of anemia or thrombocytopenia
• Enlargement of the spleen

Blast Phase

• 20% or more blast cells
• Looks like acute leukemia
• Severe symptoms
• Needs immediate intensive treatment

Early treatment will stop the disease from entering the accelerated or blast phase.

Which Diagnostic Tests and Molecular Analyses Are Used for CML?

Complete Blood Count (CBC)

Typically shows:

• Very high white blood cell count
• Elevated granulocytes
• Anemia
• Possible platelet abnormalities

Peripheral Blood Smear

Demonstrates:

• Immature myeloid cells
• Increased basophils and eosinophils

Bone Marrow Aspiration & Biopsy

Confirms diagnosis and evaluates:

• Blast percentage
• Bone marrow cellularity

Cytogenetic Analysis

It identifies the Philadelphia chromosome in bone marrow cells.

FISH Testing

The Fish test detects the BCR-ABL1 fusion gene in blood or marrow cells.

Quantitative PCR

Polymerase Chain Reaction (PCR) is used to quantify BCR-ABL1 mRNA expression.

PCR plays an important role in:

• Assessing drug efficacy
• Diagnosing minimal residual disease
• Early detection of recurrence

Mutation Testing

If resistance occurs, mutation analysis of the BCR-ABL1 kinase domain is done. Some mutations (e.g., T315I) affect TKI choice.

Risk Assessment

Scoring systems for prognosis include:

• Sokal score
• Hasford score
• EUTOS score

help determine risk category and guide treatment intensity.

How Is Chronic Myelogenous Leukemia Managed and Treated?

The primary treatment for CML is targeted therapy using Tyrosine Kinase Inhibitors (TKIs).

Treatment Goals

• Achieve complete hematologic response.
• Achieve complete cytogenetic response.
• Achieve major molecular response.
• Prevent progression to accelerated or blast phase.
• Improve survival and quality of life.

Tyrosine Kinase Inhibitors (TKIs)

TKIs block the BCR-ABL1 protein.

First-Generation TKI

• Imatinib
• First targeted therapy developed for CML
• Very effective during the chronic phase

Second-Generation TKIs

• Dasatinib
• Nilotinib
• Bosutinib

These medications can induce a more rapid and deeper molecular response.

Third-Generation TKI

• Ponatinib
• Effective against the T315I mutation
• Used in cases of resistance

TKIs are oral medications that must be taken daily, often for prolonged periods.

Treatment Response Monitoring

The reaction is scored using certain parameters:

• After three months: Early molecular response
• After six months: Cytogenetic response
• After twelve months: Major molecular response

PCR analysis should be carried out frequently.

Failure to meet response milestones may require an adjustment in treatment.

Treatment-Free Remission (TFR)

Some patients who maintain deep molecular response for at least two years may discontinue TKI therapy under strict monitoring.

These include:

• Long-term deep molecular remission
• Access to regular PCR tests
• Lack of any past drug resistance problems

It has been found that nearly 40-50% of such individuals remain disease-free even without treatment.

Management of TKI Resistance

Resistance can develop as a result of:

• Mutations in BCR-ABL1
• Non-adherence to medication
• Drug interactions

Treatment strategies involve:

• Using an alternative TKI
• Selecting drugs based on mutations
• Dose adjustment

Treatment of Accelerated and Blast Phase

Advanced-phase CML requires aggressive therapy.

Options Include:

• Second- or third-generation TKIs
• Combination chemotherapy
• Acute leukemia-type treatment protocols
• Allogeneic stem cell transplantation

Stem Cell Transplant

The following circumstances may warrant the consideration of an allogeneic hematopoietic stem cell transplant:

• Resistant disease
• Blast crisis CML
• Young patients with an available donor

It provides a potential cure but also has risks, such as:

• Graft-versus-host disease
• Infection
• Organ toxicity

Side Effects of TKIs

Common side effects include:

• Nausea
• Muscle cramps
• Fluid retention
• Tiredness
• Skin rash
• Elevated liver enzymes

The patient faces specific risks associated with the TKIs they are currently taking.

The following risks are associated with dasatinib and nilotinib use:

• Cardiovascular events
• Pleural effusion (dasatinib)
• Hyperglycemia (nilotinib)

Regular follow-up appointments help doctors identify and address potential complications.

CML produces the following medical complications.

• Blast crisis
• Severe anemia
• Infections
• Bleeding disorders
• Drug resistance
• Secondary malignancies (rare)

Adherence to therapy significantly reduces these risks.

What Long-Term Follow-Up Is Needed for CML?

The patient needs:

• Lifetime PCR testing
• Risk of heart disease testing
• Testing for bone health
• Vaccine recommendations
• Management of medication toxicity

Proper management results in most patients having a life expectancy almost equal to that of the average person.

What Is Prognosis for Chronic Myelogenous Leukemia?

The prognosis for CML has been greatly improved.

• The 10-year survival rate is above 80-90% during the chronic phase.
• Most patients attain deep molecular remission.
• Life expectancy is close to that of the general population if it is discovered early.

Prognosis is influenced by:

• Phase of disease at time of diagnosis
• Response to TKI therapy
• Mutation status
• Adherence to treatment

Blast phase CML is a worse prognosis, but can be controlled with intensive therapy and transplant.

Lifestyle & Supportive Care

The following should be considered by patients:

• Compliance with medications
• Avoidance of missed doses
• Balanced diet
• Moderate exercises.
• Protection against infection
• Follow-up check-ups.

Psychotherapy and Support Groups Enhance Coping Abilities and Adherence.

What are the Signs for Prompt Medical Attention?

Consult your doctor immediately if you have:

• High Fever
• Excessive Bleeding
• Abrupt Weakness
• Chest Pain
• Abdominal Pain
• Symptoms Worsening Quickly
• Indicators of Blast Crisis

Prompt medical intervention is the only way to save the patient from life-threatening situations.

Why choose Tender Palm Super Specialty Hospital for Chronic Myelogenous Leukemia (CML) Treatment in Lucknow, India?

Tender Palm Super-Speciality Hospital offers advanced Chronic Myelogenous Leukemia (CML) treatment in Lucknow, India, at an affordable cost. We have a team of experienced hematologists and oncology specialists who provide accurate diagnosis and both non-surgical and surgical treatment options including targeted tyrosine kinase inhibitor therapy, chemotherapy, and bone marrow transplantation procedures. Our Hematology and Oncology team has decades of experience in successfully treating Chronic Myelogenous Leukemia (CML) in Lucknow, India.

To seek an Expert consultation for Chronic Myelogenous Leukemia (CML) Treatment in Lucknow, India:

Call us at +91-9076972161
Email at care@tenderpalm.com

Request a Call Back